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Abstract 
Heart failure (HF) is a common, costly, disabling and deadly syndrome.  Heart failure is a progressive disease 
characterized by high prevalence in society, significantly reducing physical and mental health, frequent hospitalization and high 
mortality (50% of the patients survive up to 4 years after the diagnosis, the annual mortality varying from 5% to 75%). 
The purpose of this study is to develop a prognostic model with easily obtainable variables for patients with heart failure. 
Methods and Results. Our lot included 101 non-consecutive hospitalized patients with heart failure diagnosis.  
It included 49,5% women having the average age of 71.23 years (starting from 40 up to 91 years old) and the roughly 
estimated period for monitoring was 35.1 months (5-65 months). 
Survival data were available for all patients and the median survival duration was of 44.0 months.  
A large number of variables (demographic, etiologic, co morbidity, clinical, echocardiograph, ECG, laboratory and 
medication) were evaluated. We performed a complex statistical analysis, studying: survival curve, cumulative hazard, hazard 
function, lifetime distribution and density function, meaning residual life time, Ln S (t) vs. t and Ln(H) t vs. Ln (t). 
The Cox multiple regression model was used in order to determine the major factors that allow the forecasting survival and 
their regression coefficients: age (0.0369), systolic blood pressure (-0.0219), potassium (0.0570), sex (-0.3124) and the acute 
myocardial infarction (0.2662). 
Discussion.  Our model easily incorporates obtainable variables that may be available in any hospital, accurately 
predicting survival of the heart failure patients and enables risk stratification in a few hours after the patients’ presentation. 
Our model is derived from a sample of patients hospitalized in an emergency department of cardiology, some with major 
life-altering co morbidities. The benefit of being aware of the prognosis of these patients with high risk is extremely beneficial. The 
use of this model may ease the estimation of the vital prognosis, to improve the compliance and increase in the use of life-saving 
medical or surgical therapy (pacemakers, implantable defibrillators or transplantation). 
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Introduction 
Heart failure (HF) is a common, costly, disabling, 
and deadly [1] syndrome. HF is a syndrome in which a 
structural  or a functional cardiac condition impairs the 
heart’s ability to provide sufficient blood flow in order to 
meet the body's needs, or to do that at an elevated 
diastolic pressure [2]. Heart failure is a progressive 
disorder  characterized by high prevalence in society, 
significantly reduced physical and mental health [3,4] - 
reduced quality of life, frequent hospitalization and high 
mortality (50% of the patients survive for 4 years after 
diagnosis [5], the annual mortality varying from  5% to 
75%). 
Until now, the focus was to define the heart 
failure, the descriptive terms and its treatment. No system 
of diagnostic criteria has been agreed as the  gold 
standard for the heart failure. There were many definitions 
of this complex syndrome, but none was satisfactory, due 
to a lack of a universally agreed definition and to the 
challenges in the definitive/peremptory diagnosis. The 
commonly used systems were the "Framingham criteria" 
[6]  (derived from the  Framingham Heart Study), the 
"Boston criteria" [7],  the "Duke criteria" [8],  and (in the 
setting of acute myocardial infarction) the "Killip class" [9].  
The new American and European guidelines and 
recommendations include new information and have the 
declared intention to simplify and clarify the previous 
recommendations [5]. Heart failure is a clinical syndrome 
in which patients have features, symptoms typical to heart 
failure and signs typical to heart failure and objective 
evidence of a structural or functional abnormality of the 
heart at rest [5].  
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Classification of heart failure [5]: 
New onset             First presentation, Acute or slow onset 
Transient               Recurrent or episodic 
Chronic                 Persistent 
               Stable, worsening, or decompensated 
 
In recent years, the emphasis has been on 
morbidity, quality of life, costs, prognosis and mortality. In 
terms of incidence, prevalence, morbidity and mortality, 
the epidemiologic magnitude of heart failure (HF) is 
staggering.  
Heart failure is a major public healthcare 
problem reducing the quality of life, and, has a 
considerable economic cost to the individual and the 
society in general. This “cardiovascular epidemic” affects 
over 5 million people in the U.S., approximately 2% of 
adults and 10% of the elder people [10]. With an 
incidence of over 400,000 new cases diagnosed each 
year [11], and approximately 1 million hospital admissions 
annually, out of which over 80%  patients are aged over 
65 years [11, 12], the heart failure is the only major 
cardiovascular disease that increases in the United 
States. Today, it is estimated that the prevalence in the 
European countries ranges between 0.4 and 2% [13], the 
studies showing that about 14 million of the approximately 
900 million inhabitants of the 51 European countries, 
suffer from heart failure. Recent data from Statistics by 
Country for congestive Heart Failure [14] estimate an 
incidence of 0.146% (32 875) cases of heart failure and a 
prevalence of 1.76% (394 509) cases of heart failure for 
Romania. The President of the Romanian Heart Failure 
Working Group estimates the number of heart failure 
patients at approximately 800-900 000, a number 
permanently increasing [15]. 
HF morbidity is particularly important, because 
the patients with heart failure require frequent medical 
visits at home or re-hospitalization, representing a 
significant expenditure of health resources. In the first 
year after hospital discharge, approximately 50% of the 
patients with heart failure require re-hospitalization and 
the data are similar in those with systolic dysfunction or 
diastolic dysfunction. 
Some European studies show that about 1% of 
the national health budget is allocated to the therapy of 
heart failure, while in the U.S., about 2% of the national 
health budget is allocated to this problem.  The United 
States spends about $ 20 billion annually, 10% of 
healthcare budget allocated for the management of 
cardiovascular disease with heart failure, 75% of the 
amount being allocated to hospital care. Heart failure is 
the most expensive cardiological syndrome [16, 17]. 
The prognosis of individual patients differs 
considerably, outcomes in highly variable trial data and it 
often does not give an adequate direction. Taking into 
consideration the magnitude of this syndrome in the 
society and its complexity, we need a model to predict the 
risk of death, to estimate the survival of heart failure 
patients.  
Prognosis is heterogeneous and depends on a 
large number of predictors. Multiple studies and meta-
analysis highlighted various predictive criteria, but the 
latest ESC guidelines summarize the knowledge  about 
the conditions associated with a poor prognosis in heart 
failure: 
 
Table 1. Conditions associated with a poor prognosis in heart failure – according to ESC guidelines 2008 [5] 
* Powerful predictors. 
Demographics  Clinical  Electrophysiological  Functional/exertional  Laboratory  Imaging 
Advanced age * 
Ischemic etiology * 
Resuscitated 
sudden death * 
Poor compliance 
Renal dysfunction 
Diabetes 
Anemia 
COPD 
Depression 
Hypotension * 
NYHA functional clas
IV* 
Prior HF 
hospitalization * 
Tachycardia 
Pulmonary rales 
Aortic stenosis 
Low body mass inde
Sleep-related breath
disorders 
 
Tachycardia Q waves 
Wide QRS* 
LV hypertrophy 
 
Complex ventricular 
arrhythmias * 
Low heart rate variabil
Atrial fibrillation 
T-wave alternans 
 
Reduced work, low pea
VO2 * 
Poor 6-minute walk dis
High VE/VCO2 slope 
Periodic breathing 
 
 
Marked elevation of 
BNP/NT pro-BNP* 
Hyponatraemia * 
Elevated troponin * 
Elevated biomarkers
neurohumoral activat
Elevated creatinine/B
Elevated bilirubin 
Anaemia 
Elevated uric acid 
 
Low LVEF* 
Increased LV volume
Low cardiac index 
High LV filling pressu
Restrictive mitral fillin
pattern, pulmonary 
hypertension 
Impaired right 
ventricular function 
 
Generally, the inpatient mortality rate for patients 
with heart failure is of 5-20%, while the outpatient 
mortality rate remains of 20% at the end of the first year 
post diagnosis and up to 50% at 5 years post diagnosis, 
despite marked improvement in medical and device 
therapy. Each re-hospitalization increases the mortality 
rate to 20-30%. The patients with acute heart failure have 
a very severe prognosis, large randomized trials with 
hospitalized patients for decompensated heart failure 
have shown a 9.6% mortality rate at 60 days and a 
35.2%  combined mortality rate and re-hospitalization at 
60 days [18, 19]. Mortality is particularly high in patients 
with acute myocardial infarction associated with severe 
HF, with mortality close to 30% at 1 year [19, 20]. 
Existing models that predict the risk of death in 
heart failure patients have features that limit their medical 
practice applicability. These models relied on complex or 
invasive measures of cardiac performance [21].  
  211
© 2011, Carol Davila University FoundationJournal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
The identification on the persons with the high 
risk of death might bring the increase of the use with 
respect to the appropriate means available, medical and 
surgical therapy or palliative care or psychological, 
psychosocial and spiritual needs of satisfaction to the 
healthcare providers. 
The  purpose of this study is to develop a 
prognostic model easy to use for patients with heart 
failure. This model incorporates multiple variables (easily 
obtainable) clinical, laboratory and medication; the 
variables used, some of them already proved, others not 
yet, concerning the association with the increased risk of 
death. 
The incurred model aims to consider the simple 
variables that may be available in any hospital in order to 
risk stratify patients in a few hours after their presentation. 
 
Benefits expected 
Using this model either by healthcare providers 
or patients can:  
• facilitate the estimation of vital prognosis, 
• improve compliance, 
• monitor the effectiveness of drug therapies, 
• identify the medication that improves survival 
in order to increase its use  
Ability to accurately assess the prognosis would 
allow clinicians: 
• To advise patients about prognosis, 
• To sort patients 
• To make decisions about medical or surgical therapy 
(pacemakers, implantable defibrillators or transplantation) 
Methods 
Patient Population 
101 non-consecutive patients admitted in the 
Department of Cardiology, "Bagdasar-Arseni" Emergency 
Hospital with diagnosis of heart failure, were included from 
January 2005 to April 2008. We screened all the patients 
admitted with I50.0 and I50.1 codes (ICD-10-CM codes - 
International Classification of Disease, 10th Edition, 
Clinical Modification) for primary or secondary diagnosis 
of heart failure. We included only patients who accepted 
the long term follow up by the first author of the article all 
of them trusty from the point of view of compliance to 
treatment and availability to come to the medical review. 
We excluded 17 patients with incomplete baseline data. 
The criteria for the case selection were ESC guidelines 
(2005). There was only one exclusion criteria to be 
included in the study - association with aortic stenosis and 
patients with any other heart failure etiology, age, EF, or 
co morbidities could be enrolled.  
 
Data Collection   
All the demographic and in-hospital outcome 
data were collected  prospectively into a database. The 
author had full access to the data. Subsequent outcome 
and mortality data were obtained from long term follow up, 
including reviews of hospital records, outside  records, 
telephone surveys. For this analysis, the primary outcome 
- major event was death, rather than device implantation 
or cardiac transplantation. 
 
Statistical Analysis 
The database in place was de-identified. A 
series of clinical  variables previously reported to be 
associated with mortality  were evaluated. Variables 
examined were demographic data (age, sex), etiological 
(ischemic or not), co morbidity (diabetes, stroke, chronic 
obstructive pulmonary, cirrhosis, cancer, dementia), 
clinical (systolic blood pressure, heart rate, NYHA class at 
presentation,  systemic or pulmonary congestion, atrial 
fibrillation, BMI), echocardiographic (ejection fraction, left 
ventricular end diastolic diameter), the ECG (QRS> 
120ms), laboratory (hemoglobin, WBC, percentage 
lymphocytes, uric acid, lipid profile, serum ionograma  , 
creatinine, urea, glucose) and medication (ACE inhibitors, 
ß blockers, statins, allopurinol, diuretics, antiplatelet, 
anticoagulant, nitrate, calcium blockers, digitalis, 
angiotensin-receptor blocker). The types of variables are 
integer, real or boolean.  
Univariate analysis was performed initially for the 
selected data. For each variable the following elements were 
studied: Kaplan Meier survival curve,  Kaplan Meier curves of 
the Nelson-Aalen estimator for H (t) - cumulative hazard and h 
(t) hazard function, the intensity of risk, lifetime distribution 
function (life extension) F(t) =Pr(T≤t) =1-S(t), and density 
function f(t) of lifetime distribution function, Mean Residual 
Life Time (mrl),  average remaining survival time given the 
population has survived beyond t0, plot of Ln S (t) vs. t 
and plot of Ln(H)  the natural logarithm of cumulative 
hazard vs. Ln (t). 
Initially, the data were analyzed as a single 
group, than variables were analyzed based on the 
average, median, specially chosen values and in several 
subgroups. 
The key element of interest of this study is the 
survival function S defined as: S(t)=Pr(T>t)  in which t 
represents one moment in time; T is a random variable 
designating the time (or age) of death; Pr( ) notes the 
probability of occurrence of an event. Survival analysis is 
a branch of statistics dealing with the life extension of 
biological organisms and involves the estimation of the 
survival until a certain event. 
This study survival model uses hazard function 
logarithm. The parametric model of the hazard function 
logarithm, based on a multiple linear distribution, is: 
in n i i i x a x a x a t h + + + + = ... ) ( log 2 2 1 1 α   or, 
in n i i x a x a x a
in n i i i
e
x a x a x a t h
+ + + + =
+ + + + =
...
2 2 1 1
2 2 1 1
... exp( ) (
α
) α
  
In which the index n is the number of 
independent variables noted xi1,  xi2,  …,  xin index i 
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represents the number of observation, the a1, a2,…, a n, 
are the coefficients of the model, and α is the a baseline 
function.  
In order to establish the relationship between 
various variables, dependent or independent and survival, 
a multiple regression analysis was performed [22]. Cox 
multiple regression model [22], proportional hazards 
model was used for this analysis. The model 
, where   is called 
baseline hazard function, it implies the survival function 
, in which 
 is a cumulative hazard function, a is a n -
dimensional column’s vector of model parameters, with 
components a1, a2,…, a n, x is a n-dimensional column’s 
vector of independent variables with components x1  x2, 
…, xn , and T designates the sign of transposition of a 
vector. For baseline hazard function  respectively 
for  we used exponential known statistical models. 
[23]. 
in n i i x a x a x a
i e t h t h
+ + + =
...
0
2 2 1 1 ) ( ) (
x T a e e t H t S 0 ) ) ( exp( ) ( = − =
) ( 0 t H
) ( 0 t H
) ( 0 t h
x T a
) ( 0 t
e t H ) ( 0 −
h
Results 
One hundred one patients >18 years with 
diagnosis of heart failure were included. There were 50  
(49,5%) women and 51 men included, with an average 
age of 71.23 years (40-91 years) followed up for an 
average of 35.1 months (5-65 months). Survival data 
were available for all patients and  the median survival 
duration was of 44.0 months. During the follow-up 28, 
54.9% of the men and 27, 54.4% of the women died.  
 
The survival Analysis. Derivation of the Model 
Initially, the data were analyzed as a single 
group then each variable was analyzed based on the 
average, median and in several subgroups with special 
chosen values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
It was noted that for a random individual with 
heart failure, the probability of survival over t = 5 years is 
of 0,4231. Another interpretation of the values obtained is 
as it follows: 93,13% of the patients survive for one year, 
70,8% survive for more than two years, 58,01 % survive 
for more than three years, 47,95% survive for more than 
four years and only 42,31% of the population will survive 
for more than five years. It is noted that 49,8% of the 
patients survive for more than 44 months.  
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Fig. 2. Nelson-Aalen estimator for H (t), cumulative hazard, 
for the entire lot 
 
The cumulative hazard function is the integral of 
the hazard function. It can be considered as the 
probability of failure at time x given survival until time x. 
. This might alternatively be 
expressed as  . The 
cumulative hazard is the cumulative sum of the hazard. 
That means that the cumulative hazard at the failure time 
with rank K is the sum of the hazards of all failure times 
with ranks less than or equal to K. 
We can see from the data obtained that H (t), 
cumulative hazard, for the entire lot increases from 
0,0943 (at 1 year), 0,34 (2 years), 0,5373 (3 years), 
0,6874 (4 years) to 0,8454 (5 years). It is noted that at 32 
months H (t), cumulative hazard, is 0,5021. 
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Kaplan-Meier survival curve
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Fig. 3. Lifetime distribution function F (t) - life extension, for 
the entire lot 
  Fig. 1. Kaplan-Meier survival curve for the entire lot 
Lifetime distribution function F (t) is defined by 
the relation F(t) =Pr(T≤t) =1-S(t), where Pr  (T  ≤ t) 
means the probability that death time T occurs before or 
at a specified time t, the latest. 
In our lot, F (t) is monotonically increasing in 
time, this means that the likelihood of death increases as 
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subject age increased. F (t) increasing in time from 
0,0687 at 1 year, 0,292 at 2 years, 0,4092 at 3 years, 
0,502 at 4 years to 0,5769 at 5 years. We can see from 
the data obtained, that in our lot, from 42 to 48 months, F 
(t) is constant 0,502, the likelihood of death being 
constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean Residual Life Time mrl (t0) is the average 
remaining survival time, given the population has survived 
beyond t0. 
In our lot, mean residual lifetime is of 41.0802 
months, given the patients have survived beyond 5 
months, 38.0453 months at 12 months, 39.2295 months 
at 2 years and 26.2623 months, if the subjects in the 
study survived beyond 36 months. We note an increase of 
mean residual lifetime from 33.5869 to 44.9834 months at 
18 months. After 39 months the data are not available, 
they are right censored. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is useful to plot the survival distribution on a 
log scale. By doing so, we can identify the hazard rate as 
minus of the derivative of this function. A (approximate) 
straight line indicates that the exponential distribution may 
be a reasonable choice for the data. A non-straight line 
indicates that the exponential distributional assumption is 
not appropriate. 
In our lot, survival distribution S (t) on a 
logarithmic scale is a straight line for the entire lot, these 
indicating that the choice of exponential distribution of 
other common parametric models is correct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our data set, the plot of log(-logS(t)) vs. logt is 
used to check if the Weibull model is a reasonable choice 
for the survival time given. The Weibull model is not a 
reasonable choice for the data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An extremely important concept is the hazard 
function, conventionally denoted by h (t). Hazard function 
is the mortality rate at time t conditioned by survival until 
time  t or later ( ). h (t) can be defined in 
mathematical terms as: 
t T ≥
) (
) ( lim
) (
'
0 t S
t S
Δ
t T < ≤
t
t) Δt|T P(t
t h
Δt
− =
≥ +
=
→
,  in 
which  S’(t)  represents the time derivative of survival 
function. 
In our data set, we noted that the hazard function 
is not negative, this meaning that . The analysis 
of the data and the graph above denoted that the hazard 
function increasing and decreasing over time is non-
monotonic in time. The appearance of “
0 ) ( ≥ t h
bathtub 
curve hazard function” was noted; there were three such 
particular forms of the hazard function in the plot. The first 
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Fig. 4. Mean Residual Life Time (mrl), for the entire lot 
Survival distribution S (t) on a logarithmic scale
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Fig. 5. Survival distribution S (t) on a logarithmic scale, for the 
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Fig. 6. Plot of Ln(H)  the natural logarithm of cumulative 
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Kaplan Meier curve of the Nelson-Aalen estimator for h (t),  hazard function
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Fig. 7. Kaplan Meier curve of the Nelson-Aalen estimator 
for h (t) hazard function, for the entire lot. Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
curve can be described between 13 months (h (t)= 0.0206 
and 0.0417) and 20 months (h (t)= 0.0482), the second 
between 24 months (h (t)= 0.0405) and 39 months (h (t)= 
0.0396) and, the last one, between 49 months (h (t)= 
0.0784) and 62 months (h (t)= 0.1667); finally, the rate of 
"wear out" failures as the subjects exceed their lifetime 
design. The name is derived from the cross-sectional 
shape of a bathtub; the hazard function is large for small 
values of t, decreasing to some minimum and thereafter 
increasing again. This type of curve was initially described 
for technical systems, subsequently, the applicability 
being observed in survival analysis - a branch of statistics 
dealing with the life extent of biological organisms. 
Other synonyms for hazard function are the force 
of mortality (particularly used in demography and actuarial 
science) or the hazard rate. The hazard function 
represents the ratio of the probability density function to 
the survival function, S(x). 
Looking carefully in the de-identified and 
processed database, after ordering the patients, 
depending on the length of the life span, we were able to 
provide an explanation of the peaks of mortality recorded:  
-  at 13 months there were 4 deaths of 
patients > 74 years (74-79 years), three men and one 
woman, two with a Killip III acute myocardial infarction, a 
disabling myocardial infarction with low EF, 
-  at 20 and 24 months we recorded the 
deaths of 4 and respectively 3 patients with NYHA IV 
congestive heart failure, aged between 68-77 years, with 
coronary heart disease (3 of 4 and respectively 2 of 3), 
with myocardial infarction sequelae (2 of 3), with EF 30-
50%, with a history of stroke (3 patients) and chronic atrial 
fibrillation (3 patients).  
-  at 38 months there were two female 
fatalities, 67 and 82 years old,  with NYHA class III and IV 
heart failure at admission, no history of myocardial 
infarction, both smokers, with ischemic heart disease. 
-  the last peak of mortality recorded could not 
be explained by a particular subgroup of patients but by 
the normal appearance of this curve, which registers an 
increase among the human population, due to the 
approach end of the lifetime “design”. 
Studying this important concept, the hazard 
function, for the whole group or for each variable taken 
into account is extremely useful because survival models 
commonly use hazard function or hazard function 
logarithm; a parametric model of the hazard function 
logarithm, based on a multiple linear distribution can be 
written 
as
. 
in n i i x a x a x a
in n i i i e x a x a x a t h
+ + + + = + + + + =
...
2 2 1 1
2 2 1 1 ) ... exp( ) (
α α
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Fig. 8. Kaplan Meier curve of density function f(t) of lifetime 
distribution, for the entire lot 
The density function f(t) of lifetime distribution is 
defined as a continuous random variable 
dt
t dF
t f
) (
) ( = ,  for T.  If f(t) is known, we can calculate 
the probability that the time of death T will occur before or 
at the latest at a specified time t, by the relationship 
. f(t) is sometimes called 
the event density; it is the rate of death or failure events 
per unit time. 
∫ = ≤ =
t
du u f t T P t F
0
) ( ) ( ) (
The explanation of the peaks of mortality 
recorded and observed in this graph, as in the previous 
one, is that there are particular subgroups of patients. The 
explanation in detail is available above. 
Then, all variables mentioned above (40 
variables integer, real or boolean) were analyzed based 
on the average, median and specially chosen values. The 
following elements were studied for each variable: Kaplan 
Meier curves of survival curve,  for H (t) - cumulative 
hazard and h (t), F (t) - lifetime distribution function and 
density function f(t) of lifetime distribution function, MRLT 
- Mean Residual Life Time, the plot of Ln S (t) vs. t and 
plot of Ln(H)  vs. Ln (t). 
The patients' age ranged from 40 to 91 years 
old, with the average age of 71.2 years and median age 
of 69.0 years.   
If we divide our lot into two groups depending on 
average and subsequently separately analyzed, and by 
comparing the two groups, we will obtain: 
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  Fig. 9. Kaplan Meier survival curve according to age, group 1 
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The first group of patients, 40.0 - 71.2 years old, 
included 33 men, out of whom, 17 have survived, and 18 
women, out of whom, 9 have survived. The second group 
of patients, of 71.2 - 91.0 years old, includes 18 men, out 
of whom, 6 have survived, and 32 women, out of whom, 
14 have survived. 
From the graphics above, we remark that the 
survival curves start separated, after 7 months of follow-
up, with net separation after 12 months. What needs to be 
noted is the proximity of the two curves (without 
duplication) after 53 months. It is noted, that for a random 
individual with heart failure, the probability of survival 
greater than t = 5 years is of 41,76% for the first group of 
patients and 38,98% for the second group of patients.  
Comparing the two groups we obtained: 92,16% 
of the patients from the first group of patients survive for 
more than one year, and, respectively 94% of the patients 
from the second group of patients survive for more than 
one year. 76,47% and respectively 62% of the patients 
survive for more than two years, 64,525% and 
respectively 52% of the patients survive for more than 
three years, 47,73% and respectively 44,98% survive for 
more than four years. 
It was noted that 49,74% of the patients from the 
second group of patients survive for more than 38 months 
and respectively 50% of the patients from the first group 
of patients survive for more than 48 months. 
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Kaplan Meier curves of the Nelson-Aalen 
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Fig. 10. Kaplan Meier survival curve according to age, group 2 
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Fig. 12. The comparison of the Kaplan-Meier curves, of the 
Nelson-Aalen estimator for H (t) - cumulative hazard, 
according to age 
We can see from the data obtained that H (t), 
cumulative hazard, increases from 0.0396 for the patients 
from first group and respectively 0.0604 for the patients 
from the second group (at 1 year), 0.2609 and 
respectively 0.4248 (2 years), 0.4254 and respectively 
0.6207 (3 years), 0.6162 and respectively 0.7612 (4 
years) to 0.8048 and respectively 0.8945 (5 years).  
 
Fig. 11. Comparison of Kaplan-Meier survival curves in 
relation to age, 
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Fig. 13. Comparison of MRLT - Mean Residual Life Time 
curves according to age 
 
The mean residual lifetime (average remaining 
survival time) in our lot, is of 47.2297 months for the 
patients from the first group and respectively 38.7001 
months for the patients from the second group (at 6 
months follow-up), 38.0095 and respectively 32.4573 
months (at 12 months follow-up), 33.2169 and 
respectively 32.2262 months (at 18 months follow-up). 19 
months of follow-up date for the first group and are not 
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available/censored. The patients from the second group 
have 39.3577 months (at 2 years), 26.6651 (at 3 years) 
and 14.3077 (at 4 years). 
From the graphics above, we can remark that 
the survival curves start separating after 5 months of 
follow-up, with a net separation after 12. The proximity of 
the two curves can be denoted between 9-11 months.    
Comparing the two groups we obtain the 
following: 96,04% of the patients from the first group, 
survive for more than one year, and respectively 94,16% 
of the patients from the second group, survive for more 
than one year; 78,41% and respectively 63,3% of the 
patients, survive for more than two years, 62,72% and 
respectively 55,36% of the patients survive for more than 
three years, 51,93% and respectively 47,36% survive for 
more than four years. It was noted that, for a random 
individual with heart failure, the probability of survival 
greater than t = 5 years is of 45,23 for the first group of 
patients and 38,95 for the second group of patients.  
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We observed that 50,32% of the patients from 
the second group survive for more than 42 months, and 
respectively 50% of the patients from the first group of 
patients, survive for more than 48 months.    
 
 
Fig. 14. The survival distribution S (t) on a logarithmic scale 
according to age groups 
 
 
 
  The survival distribution S (t) on a logarithmic 
scale in our lot is a straight line for both age groups, these 
indicating that the exponential distribution may be a 
reasonable choice for the data. 
 
 
 
  There were 50 (49,5%) women and 51 men 
included in our lot. We can divide our lot into two groups: 
group 1 - women and group 2 – men, subsequently being 
analyzed separately and in comparison.  
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Fig. 16. Comparison of Kaplan-Meier survival curves 
according to NYHA class, group 2 - patients with NYHA 
class II , group 3 - patients with NYHA class III and 
respectively group 4 - patients with NYHA class IV at the 
time of admission to hospital 
 
We included 64 patients (34 men, 30 women) 
with NYHA class IV in our lot, at the time of admission to 
hospital, 33 patients (15 men, 18 women) with NYHA 
class III and respectively 4 patients (2 men, 2 women) 
with NYHA class II (table 2). 
 
Fig. 15. Comparison of Kaplan-Meier survival curves 
according to sex, group 1 - women and group 2 - men 
      Table 2. Patients’ survival according to NYHA class and gender 
NYHA class  at the time of 
admission to hospital 
Men  Men who 
died 
Men who 
have survived 
Women  Women who 
died 
Women who 
have survived 
NYHA class IV   34  22  12  30  18  12 
NYHA class III     15  6  9  18  8  10 
NYHA class  II  2  0  2  2  1  1 
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Analyzing the survival curves in the figure above, 
we remarked that the survival curves start separating after 
5 months of follow-up, with a net separation after 20 
months (patients with NYHA class IV and III, the 4 
patients with NYHA class II have a net positive evolution 
from the rest of the subjects, but their number is too small 
for statistical analysis).  The proximity of the two curves 
(NYHA class IV and III) is denoted between 5-20 months.  
Comparing the groups of patients with NYHA 
class III and IV we obtained the following: 91,09% of the 
patients from the group of patients with NYHA class III, 
survived for more than one year, and respectively 96,9% 
of the patients from the group of patients with NYHA class 
IV, survived for more than one year; 75,91% and 
respectively 66,34% of the patients, survived for more 
than two years, 69,96% and respectively 51,13% of the 
patients survived for more than three years, 61,56% and 
respectively 42,34% survived for more than four years. It 
was noted that, for a random individual with heart failure, 
the probability of survival greater than t = 5 years is of 
53,36 for the group of patients with NYHA class III and 
34,22 for the group of patients with NYHA class IV.  
We observed that 50% of the patients from the 
second group of patients (NYHA class IV) survive for 
more than 37 months and respectively 50% of the 
patients from the first group of patients (NYHA class III) 
survive for more than 62 months.  
The analysis of Kaplan-Meier survival curves, 
according to ejection fraction (FE), can be made 
according to the mean (fig. 17) and median (fig. 18, more 
sensitive statistically) rates, or according to special 
clinically important intervals (fig. 19). We only presented 
the survival of patients on three intervals, considering the 
small size of the article. 
 
           Table 3. Patients’ survival according to ejection fraction class and gender 
Ejection fraction  Men  Men who  
died 
Men who  
have survived 
Women   Women who 
died 
Women who  
have survived 
group 1 FE 15.0 -30.0%,   17  14  3  6  5  1 
group 2 FE 30.0- 50.0%  32  14  18  36  19  17 
group 3 FE 50.0- 60.0%  2  0  2  8  3  5 
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Fig. 17. Comparison of Kaplan-Meier survival curves 
according to the ejection fraction (two groups according to 
mean, group 1 FE 15.0 - 40.9%, group 2 FE 40.9 - 60.0%) 
Fig. 19. Comparison of Kaplan-Meier survival curves 
according to the ejection fraction (3 groups, group 1 FE 15.0 
- 30.0%, group 2 FE 30.0- 50.0%, group 3 FE 50.0- 60.0%) 
 
Comparison of Kaplan-Meier survival curves 
according to ejection fraction (median)
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While analyzing the survival curves in the figure 
above, we remarked that the survival curves of patients 
within FE group 1 and 2, started separating after 5 
months of follow-up; the 10 subjects in group 3 had a net 
positive evolution from the rest of the subjects. 
Comparing the three FE groups of patients we 
obtained the following: 87,14% of the patients from the 
first group, survived for more than one year, 98,53% of 
the patients from the second group, survived for more 
than one year and respectively 90% of the patients from 
the third group, survived for more than one year; 53,24%, 
75,42% and respectively 80% of the patients, survived for 
more than two years, 40,54% 63,72% and respectively 
70% of the patients, survived for more than three years, 
28,03%, 54,77% and respectively 70% of the patients, 
Fig. 18. Comparison of Kaplan-Meier survival curves 
according to the ejection fraction (two groups according to 
median, group 1 FE 15.0 - 33.0%, group 2 FE 33.0- 60.0%) 
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survived for more than four years. It was noted, that for a 
random individual with heart failure, the probability of 
survival greater than t = 5 years is of 0 for the group of 
patients with FE 15.0 - 30.0% and 49,15% for the group of 
patients with FE 30.0- 50.0%. 
We observed that 53,24% of the patients from 
the first group, survived for more than 24 months and 
54,77% of the patients from the second group, survived 
for more than 24 months.  
The analysis of Kaplan-Meier survival curves 
according to left ventricular end diastolic diameter 
(LVEDD), can be made according to the mean (54.6 mm) 
and median (65.0 mm, more sensitive statistically) rates, 
or according to a chosen value (60.0 mm). We will only 
present the survival of patients according to a chosen 
value, 60.0 mm of left ventricular end diastolic diameter. 
 
 
 
 
 
 
 
 
 
 
 
 
While analyzing the survival curves in the figure 
above, we remarked that the survival curves of the 
patients within LVEDD group 1 and 2, started separating 
after 36 months of follow-up. 
Comparing the two LVEDD groups of patients 
we obtained the following: 96,23% of the patients from the 
first group, survived for more than one year, and 
respectively 90,91% of the patients from the second 
group, survived for more than one year; 72,59% and 
respectively 63,8% of the patients, survived for more than 
two years, 58,8% and respectively 54,3% of the patients, 
survived for more than three years, 52,54%, and 
respectively 39,93% of the patients, survived for more 
than four years. It was noted, that for a random individual 
with heart failure, the probability of survival greater than t 
= 5 years is of 47,97% for the group of patients with 
LVEDD 37.0  - 60.0 mm and 0 for the group of patients 
with LVEDD 60.0- 82.0 mm. In fact, after 54 months of 
follow-up no patient in group 2 survived any longer. 
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We observed that 50% of the patients from the 
first group, survived for more than 49 months and 50% of 
the patients from the second group, survived for more 
than 37 months.  
The analysis of the Kaplan-Meier survival 
curves, according to the heart rate (HR), can be made 
according to the mean (100 b/min) or median (64.0 b/min) 
values.  
Fig. 20. Comparison of Kaplan-Meier survival curves according to 
left ventricular end diastolic diameter (LVEDD) (2 groups, group 1 
LVEDD 37.0  - 60.0 mm, group 2 LVEDD 60.0- 82.0 mm)   
 
 
         Table 4. The patients’ survival according to heart rate (HR) and gender 
Heart rate (HR)  Men  Men who died  Men who 
survived 
Women   Women who  Women who 
survived 
group 1  
HR 40.0 -100 b/min,  
36  19  17  25  13  12 
group 2  
HR 100 -270.0 b/min 
15  9  6  25  14  11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While analyzing the survival curves in the figure 
above, we remarked that the two curves start separating 
after 9 months of follow-up. Comparing the two HR groups of 
patients we obtain the following: 93,44% of the patients from 
the first group, survived for more than one year, and 
respectively 97,5% of the patients from the second group, 
survived for more than one year; 65,57% and respectively 
77,5% of the patients, survived for more than two years, 
55,53% and respectively 62,5% of the patients, survived for 
more than three years. It should be noted that, after 39 
months, the two curves showed a similar, close survival of 
the patients in the two groups. We observed that 50% of the 
patients from the two groups, survived for more than 42 
months. 
Comparison of Kaplan-Meier survival curves in 
relation to heart rate
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The analysis of Kaplan-Meier survival curves, 
according to the systolic blood pressure (TAS), can be made 
according to the mean (141.5 mmHg) or median (125.0 
mmHg) values. We can see the distribution and survival of 
the patients according to SBP and sex, in table 5.  
Fig. 21.  Comparison of Kaplan-Meier survival curves 
according to heart rate (2 groups, group 1 HR 40.0 -100 
b/min, group 2 HR 100 -270.0 b/min). 
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      Table 5. The patients’ survival according to systolic blood pressure and gender 
 
Systolic blood pressure (SBP) 
Men  Men who died  Men who 
survived 
Women   Women who died  Women who 
survived 
group 1  
SBP 70.0 - 141.5 mmHg  
31  24  7  28  18  10 
group 2  
SBP 141.5 - 240.0 mmHg 
20  4  16  22  9  13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While analyzing the survival curves in the figure 
above, we remarked that the two curves start separating 
after 12 months of follow-up. Comparing the two SBP 
groups of patients we obtain the following: 94,92% of the 
patients from the first group, survived for more than one 
year, and respectively 95,24% of the patients from the 
second group, survived for more than one year; 59,32%, 
and respectively 85,71% of the patients, survived for more 
than two years, 43,86% and respectively 78,57% of the 
patients, survived for more than three years, 29,78% and 
respectively 75,77% of the patients, survived for more 
than four years. It was noted, that for a random individual 
with heart failure, the probability of survival greater than t 
= 5 years is of 19,15% for the first group of patients and 
67,35% for the second group of patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mean residual lifetime (average remaining 
survival time) in our lot is of 22.7877 months for the 
patients from first group and respectively 51.8057 months 
for the patients from the second group (at 12 months 
follow-up), 19.1398 and respectively 38.5953 months (at 
24 months follow-up), 16.1172 and respectively 26.324 
months (at 3 years). 
Comparison of Kaplan-Meier survival curves 
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Patients with acute myocardial infarction and 
patients with a history of myocardial infarction were 
included in our group. Two boolean variables are 
considered in the charts below.   
There were 30 patients with a history of 
myocardial infarction: 19 men and 11 women (fig. 23). 
Comparing the two groups of patients (group 1 with a 
history of myocardial infarction, group 2 without a history 
of myocardial infarction) we obtained the following: 
93,44% of the patients from the first group, survived for 
more than one year, and respectively 97,04% of the 
patients from the second group, survived for more than 
one year; 73,52%, and respectively 77,71% of the 
patients, survived for more than two years, 57,46% and 
respectively 68,82% of the patients, survived for more 
than three years, 53,2% and respectively 57,85% of the 
patients, survived for more than four years. It was noted, 
that for a random individual with heart failure, the 
probability of survival greater than t = 5 years is of 45,02% 
for the first group of patients and 53,52% for the second 
group of patients.  
Fig. 22. Comparison of Kaplan-Meier survival curves 
according to the systolic blood pressure (2 groups, group 1 
SBP 70.0 - 141.5 mmHg, group 2 SBP 141.5 - 240.0 
mmHg).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of Kaplan-Meier survival curves in relation to 
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Fig. 24. Comparison of Kaplan-Meier survival curves 
according to a history of myocardial infarction (2 groups, 
group 1 with a history of myocardial infarction, group 2 
without a history of myocardial infarction).  
Fig. 23. Comparison of mean residual lifetime curves 
according to the systolic blood pressure (2 groups, group 1 
SBP 70.0 - 141.5 mmHg, group 2 SBP 141.5 - 240.0 
mmHg).  
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We can see from the data obtained, that the 
cumulative hazard value is almost double in the first two 
years for the patients with a history of myocardial 
infarction, then the difference is significant but slightly 
smaller: 0.1347 for the patients from first group and 
respectively 0.0667 for the patients from the second 
group (at 1 year), 0.5297 and respectively 0.2966 (2 
years), 0.7233 and respectively 0.5352 (3 years), 1.0199 
and respectively 0.6093 (4 years) to 1.172 and 
respectively 0.7632 (5 years). 
There were 11 patients with an acute myocardial 
infarction: 2 men and 9 women, an insufficient number for 
the statistical analysis (fig. 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the smoking status, the lot was 
divided into two groups: group 1 - 28 smoking patients (19 
men and 9 women) and group 2 – 73 non-smoking 
patients (32 men and 41 women). In up to 38 months of 
follow-up it could be seen that the values of cumulative 
hazard were similar, subsequently denoting an increase 
of the cumulative hazard for smoking patients: 0.3259 for 
first group and respectively 0.3455 for the second group 
of patients (2 years), 0.6646 and respectively 0.5623 (38 
months), 0.9171 and respectively 0.5935 (4 years) and 
0.9171 and respectively 0.7906 (5 years). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to the presence of diabetes mellitus, 
the lot was divided into two groups: group 1 - 36 patients 
with diabetes mellitus (18 men and 18 women) and group 
2 – 65 patients without diabetes mellitus (33 men and 32 
women). Comparing the two groups of patients we 
noticed that: the two survival curves were separating after 
9 months; 97,22% of the patients from the first group, 
survived for more than one year, and respectively 93,92% 
of the patients from the second group, survived for more 
than one year; 83,33%, and respectively 63,69% of the 
patients survived for more than two years, 69,78% and 
respectively 52,89% of the patients, survived for more 
than three years, 61,06% and respectively 43,02% of the 
patients, survived for more than four years. It was noted, 
that for a random individual with heart failure, the 
probability of survival greater than t = 5 years was of 
55,97% for the first group of patients and 33,36% for the 
second group of patients.  
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Fig. 25. Comparison of Kaplan-Meier curves of the Nelson-
Aalen estimator for H (t) - cumulative hazard, according to a 
history of myocardial infarction (group 1 with a history of 
myocardial infarction, group 2 without a history of 
myocardial infarction).  
Comparison of Kaplan-Meier curves according to 
the presence of an acute myocardial infarction
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Fig. 26. Comparison of Kaplan-Meier survival curves 
according to the presence of an acute myocardial infarction 
(group 1 with acute myocardial infarction, group 2 without 
acute myocardial infarction).  
Comparison of the Nelson-Aalen estimator curves 
for H (t) according to smoking status
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Fig. 27. Comparison of Kaplan-Meier curves of the Nelson-
Aalen estimator for H (t) - cumulative hazard, according to 
smoking status.  
Comparison of Kaplan-Meier curves according to the 
presence of diabetes, both groups   
0
0.2
0.4
0.6
0.8
1
1.2
0 2 04 06 08 0
t survival [months]
S
(
t
)
 
[
-
]
   S2
  S1
Fig. 28. Comparison of Kaplan-Meier survival curves 
according to the presence of diabetes mellitus (group 1 with 
diabetes mellitus, group 2 without diabetes mellitus).  
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Another variable, which was carefully analyzed, 
was the hemoglobin value at admission; the variable was 
analyzed based on the average, median and several 
especially chosen subgroups of values. The lot was 
divided into three groups: group 1 patients with Hb 
between 8.6 - 9.5 gr/dl, group 2 patients with Hb between 
9.5 - 12.5 gr/dl, group 3 patients with Hb between 12.5 - 
17.3 gr/dl (Fig. 29).  
The  first group  consisted of four patients, thus 
the statistical  significance was low.  The  three  survival 
curves separated after 7 months. Comparing the three 
groups, we obtained the following: 100% of the patients 
from the first group, survived for more than one year, and 
respectively 93,55% of the patients from the second 
group, survived for more than one year; 95,48 of the 
patients from the third group, survived for more than one 
year, 0% , 68,2% , and respectively 75,9% of the patients, 
survived for more than two years, 52,4% (group 2) and 
respectively 65,34% (group 3) of the patients, survived for 
more than three years, 37,75% (group 2)  and 
respectively 57,99% (group 3), survived for more than 
four years. It was noted, that for a random individual with 
heart failure, the probability of survival greater than t = 5 
years was of 37,75% for the second group of patients and 
47,69% for the third group of patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other variables carefully analyzed were Na and 
K values at admission; the variables were analyzed based 
on the average, median and several especially chosen 
subgroups of values. 
The lot was divided into two groups according to 
serum K value: group 1 - patients with K 3.3 - 3.5 mEq/L, 
group 2 - patients with K 3.5 - 5.8 mEq/L. (Fig. 30). The 
first group consisted of six patients, thus the statistical 
significance was low. The two survival curves separated 
after 5 months. Comparing the two groups we obtained: 
100% of the patients from the first group of patients, 
survived for more than one year, and respectively 94,78% 
of the patients from the second group, survived for more 
than one year; 83,33% , and respectively 70% of the 
patients, survived for more than two years, 66,67% and 
respectively 58,61% of the patients, survived for more 
than three years, 66,67% and respectively 48,8% 
survived for more than four years. It was noted, that for a 
random individual with heart failure, the probability of 
survival greater than t = 5 years was of 66,67% for the 
first group of patients and 40,62% for the second group of 
patients.  
 
 
 
 
 
 
 
 
 
Comparison of Kaplan-Meier survival curves according to 
serum K value
0
0.2
0.4
0.6
0.8
1
1.2
0 1 02 03 04 05 06 07 0
t survival (months)
S
(
t
)
 
[
-
]
   S1
  S2
 
 
 
 
 
Fig. 30. Comparison of Kaplan-Meier survival curves 
according to serum K value (group 1 K 3.3 - 3.5 mEq/L, 
group 2 K 3.5 - 5.8 mEq/L).  
The lot was divided into two groups according to 
serum Na value: group 1 - patients with Na value at 
admission of 117 - 135 mEq/L, group 2 - patients with Na 
value at admission of 135 - 148 mEq/L. (Fig. 31). The first 
group consisted of 12 patients and the second had 89 
subjects. The two survival curves separated after 5 
months. Comparing the two groups we obtained: 91,67% 
of the patients from the first group of patients, survived for 
more than one year and respectively 95,54% of the 
patients from the second group, survived for more than 
one year; 35,8% and respectively 75,67% of the patients, 
survived for more than two years, 35,8% and respectively 
62,36% of the patients, survived for more than three 
years, 26,85% and respectively 52,93% of the patients, 
survived for more than four years. It was noted that for a 
random individual with heart failure, the probability of 
survival greater than t = 5 years was of 0 % for the first 
group of patients and 44,02% for the second group of 
patients.  
Comparison of Kaplan-Meier survival curves according to 
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Fig. 29. Comparison of Kaplan-Meier survival curves 
according to hemoglobin value (group 1 Hb 8.6 - 9.5 gr/dl, 
group 2 Hb 9.5 - 12.5 gr/dl, group 3 Hb 12.5 - 17.3 gr/dl).  
 
 
 
 
 
 
 
 
 
 
Comparison of Kaplan-Meier survival curves according to 
Na value
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Fig. 31. Comparison of Kaplan-Meier survival curves 
according to serum Na value (group 1 - patients with Na 
value at admission of 117  - 135 mEq/L, group 2 - patients 
with Na value at admission of 135 - 148 mEq/L).  
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The lot was divided into two groups: group 1 - patients 
with beta-blockers in therapy, group 2 - patients without 
beta-blockers, see table 5 – The patients’ survival 
according to the treatment with beta-blockers and gender. 
Another variable carefully analyzed was the 
existence of certain classes of drugs in therapy. Due to 
the limited size of the article, we have only analyzed the 
patients’ evolution according to the use of beta-blockers 
or angiotensin converting enzyme inhibitors. 
 
Table 6. The patients’ survival according to the treatment with beta-blockers and gender 
 
Therapy  
Men  Men who died  Men who 
survived 
Women   Women who  Women who 
survived 
group 1  
with beta blokers 
15  7  8  16  9  7 
group 2  
without beta blokers 
36  21  15  34  18  16 
 
The two survival curves separated after 5 
months. Comparing the two groups we obtained the 
following: 93,55% of the patients from the first group of 
patients, survived for more than one year, and 
respectively 95,73% of the patients from the second 
group, survived for more than one year; 80,87%, and 
respectively 66,39% of the patients, survived for more 
than two years, 64,91% and respectively 56,55% of the 
patients, survived for more than three years, 54,6% and 
respectively 47,67% of the patients, survived for more 
than four years. It was noted that for a random individual 
with heart failure, the probability of survival greater than t 
= 5 years was of 49,14% for the first group of patients and 
47,69% for the second group of patients.  
© 2011, Carol Davila University Foundation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We included 68 patients (32 men, 36 women) 
with angiotensin converting enzyme inhibitors in our lot, 
and respectively 33 patients (19 men, 14 women) without 
angiotensin converting enzyme inhibitors in therapy. 
The two survival curves started separating after 
13 months, with a net difference after 20 months of follow 
up. Comparing the two groups we obtained the following: 
92,73% of the patients from the first group, survived for 
more than one year, and respectively 93,94% of the 
patients from the second group, survived for more than 
one year; 68,21%, and respectively 67,54% of the 
patients, survived for more than two years, 60,84% and 
respectively 55,54% of the patients, survived for more 
than three years, 53,87% and respectively 41,7% of the 
patients, survived for more than four years. It was noted, 
that for a random individual with heart failure, the 
probability of survival greater than t = 5 years was of 
42,84% for the first group of patients and 0% for the 
second group of patients.  
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Comparison of Kaplan-Meier survival curves according to 
treatment with beta blockers
0
0.2
0.4
0.6
0.8
1
1.2
0 2 04 06 08 0
t survival [months]
S
(
t
)
 
[
-
]
   S1
  S2
 
 
 
 
 
 
Fig. 33. Comparison of Kaplan-Meier survival curves 
according to treatment with angiotensin converting enzyme 
(ACE) inhibitors (group 1 - patients with ACE inhibitors in 
therapy, group 2 - patients without ACE inhibitors in 
therapy).  
Fig. 32. Comparison of Kaplan-Meier survival curves 
according to treatment with beta-blockers (group 1 -patients 
with beta-blockers in therapy, group 2 - patients without Na 
beta-blockers in therapy).  
In univariate analyses, a series of variables were 
associated with increased mortality: demographic data 
(age, sex), etiology (acute or history of myocardial 
infarction), co morbidity (diabetes, stroke, chronic 
obstructive pulmonary, cirrhosis, cancer, dementia), 
smoking status, clinical (systolic blood pressure, heart 
rate, NYHA class at presentation, systemic or pulmonary 
congestion,), echocardiographic data (ejection fraction, 
left ventricular end diastolic diameter), the ECG (QRS> 
120ms), laboratory data (hemoglobin, WBC, Na and K 
value, creatinine, glucose), medication (ACE inhibitors, ß 
blockers, statins, diuretics dose, antiplatelet, calcium 
blockers, angiotensin-receptor blocker) and absence of 
percutaneous transluminal coronary angioplasty. The 
types of variables are integer, real or boolean. Atrial 
fibrillation, allopurinol, nitrate, anticoagulant and digitalis Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
were not associated with increased mortality in univariate 
analysis. 
In order to determine the major factors that allow 
the forecasting survival (or mortality), we used Cox 
multiple regression model; proportional hazards model 
[20]. All the data was used in a regression analysis, using 
Cox proportional-hazards in order to identify the 
regression coefficients of each variable. 
Age and gender were forced into the model as 
important demographic  variables. After many trials the 
best results obtained were the following: convergence 
achieved after 17 iterations, for criteria eps2LL = 
0.000010; coefficients for each explanatory variable were: 
0.0369 (age), -0.0219 (SBP), 0.0570 (Potassium), -0.3124 
(sex) and 0.2662 (acute myocardial infarction). Knowing 
the values of regression coefficients, we had all the 
elements of the survival function equation. A positive 
regression coefficient for an explanatory variable meant 
that the hazard was higher and thus the prognosis worse. 
Conversely, a negative regression coefficient implies a 
better prognosis for patients with higher values of that 
variable. Interpreting the Cox model involves examining 
the coefficients for each explanatory variable. The impact 
of adding boolean variables was negative at repeated 
testing. Accuracy of the model across data sets can be 
improved by optimizing regression coefficients by 
repeated testing.  
Discussion 
Our model accurately predicts survival of heart 
failure patients with the use of commonly obtained clinical 
characteristics. The score indicated that age, systolic 
blood pressure, potassium, sex and acute myocardial 
infarction had independent predictive power. The impact 
of adding boolean variables was negative at repeated 
testing. The accuracy of the model can be improved by 
repeated testing and adding other variables and further 
investigation  is warranted. There were no patients with 
implantable devices in our study group, so the model did 
not allow the estimation of the benefit of adding devices to 
an individual patient’s therapeutic regime. 
The model easily incorporates obtainable 
variables that may be available in any hospital, in order to 
risk stratify patients in a few hours after presentation. 
Previous heart failure risk models required invasive 
hemodynamic measurements [21].  
Our model is derived from a sample of patients 
hospitalized in an emergency department of cardiology 
and  has not been previously validated among non-
hospitalized patients. Another model was developed and 
validated among outpatients participating in clinical trials, 
clinical registries or observational studies; therefore, the 
model may not be generalized to hospitalized patients or 
those with major life-altering co morbidities. The benefit of 
knowing the prognosis of these patients with high risk is 
enormous. The applicability of the model in the general 
population of patients with heart failure has not been 
tested.  
Conclusion 
The model developed provides an estimate of 
survival in patients with acute heart failure using a few 
variables, easily obtainable in any hospital. There are 
many applications of such a model, which may estimate 
the survival of a hospitalized patient with heart failure. The 
use of this model may facilitate the estimation of vital 
prognosis, improve compliance, and increase the use of 
life-saving medical or surgical therapy (pacemakers, 
implantable defibrillators or transplantation). 
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